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We present the long-term results of 18 chemotherapy relapsed indolent (N¼ 12) or transformed (N¼ 6) NHL patients of a phase II
anti-CD20 131I-tositumomab (Bexxars) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody
combined with 131I-tositumomab once as dosimetric and once as therapeutic activity delivering 75 or 65 cGy whole-body radiation
dose to patients with normal or reduced platelet counts, respectively. Two patients were not treated due to disease progression
during dosimetry. The overall response rate was 81% in the 16 patients treated, including 50% CR/CRu and 31% PR. Median
progression free survival of the 16 patients was 22.5 months. Median overall survival has not been reached after a median observation
of 48 months. Median PFS of complete responders (CR/CRu) has not been reached and will be greater than 51 months. Short-term
side effects were mainly haematological and transient. Among the relevant long-term side effects, one patient previously treated with
CHOP chemotherapy died from secondary myelodysplasia. Four patients developed HAMA. In conclusion, 131I-tositumomab RIT
demonstrated durable responses especially in those patients who achieved a complete response. Six of eight CR/CRu are ongoing
after 46–70 months.
British Journal of Cancer (2006) 94, 1770–1776. doi:10.1038/sj.bjc.6603166 www.bjcancer.com
Published online 9 May 2006
& 2006 Cancer Research UK
Keywords: radioimmunotherapy; Non-Hodgkin lymphoma; long-term follow-up; 131I-tositumomab





















































Advanced stage follicular non-Hodgkin’s lymphoma (NHL) is
considered incurable by conventional therapy, while localized
stage 1 or 2 NHL may be cured with external beam radiation
therapy of involved sites (Mac Manus and Hoppe, 1996). Current
radioimmunotherapy (RIT) is to be considered a combination of
systemic radiation therapy and antibody-based immunotherapy.
Both treatments reach tumour sites after i.v. application. Each of
the two modalities, the unlabelled anti-CD20 antibody therapy and
the corresponding RIT have been shown to be effective in follicular
NHL (Buchsbaum et al, 1992; Kaminski et al, 1993; McLaughlin
et al, 1998; Kaminski et al, 2005). The optimal combination of the
two therapy strategies might have the potential to cure even
advanced stage disease.
Recently, two radiolabelled antibodies targeting the CD20
antigen have been shown to lead to high percentages of complete
remissions (Kaminski et al, 2000; Witzig et al, 2002b). Long lasting
durable responses were reported for patients treated with 131I-
tositumomab either upfront (Press et al, 2003; Kaminski et al,
2005; Leonard et al, 2005) or at recurrence after chemotherapy
(Kaminski et al, 2000, 2001; Vose et al, 2000; Davies et al, 2004;
Horning et al, 2005). A recent pooled analysis of studies in the
relapsed/refractory disease setting has demonstrated long-term
durable responses lasting 4 years or more associated with a single
treatment of 131I-tositumomab (Fisher et al, 2005). Similar
response rates including durable responses were reported for
RIT with 90Y-ibritumomab tiuxetan (Zevalins) (Gordon et al,
2004b).
Compared with RIT based on 131I-labelled antibodies that has to
be performed in specially equipped radioprotection units in
Europe, using 90Y as the label allows outpatient treatment. In the
US, 131I-tositumomab is administered as an outpatient treatment.
The use of 131I also has clinical advantages. The low energy
electrons are well adapted for treatment of small or minimal
disease (Sharkey et al, 1991; Vogel et al, 1997) and the long
experience with 131I-therapy of thyroid disease has shown excellent
tolerance (Hall et al, 1992; Schlumberger and De Vathaire, 1996).
Labelling with 131I can be performed while completely maintaining
antibody immunoreactivity (Schaffland et al, 2004). The use of
dosimetry for 131I-tositumomab allows for patient specific dosing.
Recently, a particularly high percentage of long lasting complete
responses was reported by Davies et al (2004) in 41 relapsed
patients treated in England with 131I-tositumomab. As the second
European centre participating in this multicentre study, we report
here the experience from Switzerland with the particular focus on
the long-term efficacy of this 131I-RIT.
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PATIENTS AND METHODS
This single arm, open-label phase II study of Corixa Corp., South
San Francisco, CA and GlaxoSmithKline, Philadelphia, PA,
USA aimed to establish the response rate to 131I-tositumomab in
patients after first or multiple recurrences of indolent or
transformed B-cell lymphoma. Duration of response, safety and
survival were secondary end points. The study was conducted in
two centres in Switzerland. Patients gave their written informed
consent to the study protocol that had been approved by the local
Ethics Committees of the University Hospitals of Lausanne and
Geneva as well as the Radioprotection Section of the Swiss Federal
Office of Public Health.
Patient eligibility
Patients had to present a histologically confirmed, CD20 positive
follicular, small lymphocytic or MALT non-Hodgkin’s B-cell
lymphoma, in relapse after at least one full regimen of
chemotherapy. Patients with transformed NHL were also eligible.
Measurable minimal two-dimensional tumour diameter was
X2 cm. A HAMA (human anti-mouse antibody) test had to be
negative at study entry. Adequate bone marrow function was to be
documented with neutrophils X1.5 109 l1 and platelets
X100 109 l1. Maximal acceptable lymphoma infiltration of bone
marrow was 25%, as determined with trephine biopsy.
A minimal waiting period of 4 weeks was required after
cytotoxic chemotherapy, radiotherapy or cytokine therapy. Pa-
tients having had high-dose chemotherapy or radiation therapy
including stem cell rescue were excluded from the study as well as
patients with known HIV infection, active hydronephrosis, and
those treated previously with RIT.
Dosimetric and therapeutic antibody administrations
Unlabelled and radiolabelled antibody tositumomab was provided
by Corixa Corp., South San Francisco, CA and GlaxoSmithKline,
Philadelphia, PA, USA. Dosimetric and therapeutic 131I-labelling of
tositumomab was performed centrally (MDS Nordion Inc., Kanata,
Canada) and the labelled compound was shipped frozen on a
per patient basis. Two arbitrarily selected therapeutic batches of
131I-tositumomab were analysed for immunoreactivity using the
Lindmo approach (Lindmo et al, 1984). Immunoreactivity was
measured immediately after upfreezing the batches for injection of
patients. About 6 ng 131I-tositumomab were incubated for 2 h at
371C with five serial dilutions of 1 –10 106 fresh, exponentially
grown Raji or Daudi B lymphoma cells in duplicates. Cell-bound
activity was determined and expressed in % of incubated activity,
specific binding, after subtraction of nonspecific binding, was
determined and expressed as percent of incubated activity and
immunoractivity determined using double inverse plot (Lindmo
et al, 1984) with extrapolation at infinite antigen excess.
Patient preparation included thyroid blocking with 2 100 mg
KI per day orally and premedication with 500 mg paracetamol
and 2 mg clemastine, taken orally. Unlabelled and radiolabelled
tositumomab regimen consisted of two steps as described
previously (Kaminski et al, 1993; Kaminski et al, 2005). Shortly,
in the first dosimetry step, patients received 450 mg unlabelled
tositumomab in a 1 h infusion followed immediately by that of
35 mg 131I-tositumomab (185 MBq). The second, therapeutic step
consisted again of the infusion of 450 mg unlabelled tositumomab
over 1 h followed by that of 35 mg 131I-tositumomab labelled with
the activity calculated to deliver 75 cGy total body dose for patients
with normal, and 65 cGy for patients with reduced platelet counts
(100–150 G l1).
For dosimetry, patients were scanned with a large field of view
dual head gamma camera (BIAD, Trionix, Twinsburg, Ohio, or
Prism 2000, Picker) equipped with high-energy parallel collimators
and using a matrix of 1024 256. Camera uniformity, background
and energy peaks were checked daily. Scanning was performed as
described by Wahl et al (1998). Patients were scanned under
identical conditions, on day 0 immediately after antibody
perfusion (referred to as 100% reference scan), on day 2, 3 or 4
and on day 6 or 7. The background corrected activities of days 2, 3
or 4 and day 6 or 7 were expressed in % of activity measured on
day 0 and fitted to a semi-logarithmic scale allowing to directly
read, from the exponential curve-fit, the whole-body effective half-
life and retention time of 131I-labelled tositumomab. Using the
published tabulated whole-body dosimetry data (Wahl et al, 1998),
the 131I-tositumomab activity was extrapolated that delivered
75 cGy to patients with normal BM function or 65 cGy to patients
with reduced platelet counts.
Response evaluation
Tumour response evaluation, including physical examination,
computed tomography (CT) of the neck, chest, abdomen and
pelvis and bone marrow biopsy if involved before treatment, was
performed at weeks 13 and 26 and every 6 months thereafter until
disease progression or death. A complete response (CR) was
defined as complete resolution of all disease-related radiologic
abnormalities and clinical symptoms. An unconfirmed CR
(CRu) was defined as complete resolution of clinical disease
symptoms and residual focal stable radiologic abnormalities
of p2 cm diameter according to the International Workshop
criteria (Cheson et al, 1999). A partial response (PR) was defined
as 450% reduction of two-dimensional tumour size and
progressive disease as X25% increase of the two-dimensional
tumour size. Progression free survival (PFS) was defined as time
from treatment initiation to first documentation of progression or
death and overall survival (OS) as time from treatment start to
death.
Evaluation of toxicity and safety
All adverse events from study entry through to week 13 were
graded according to the National Cancer Institute Common
toxicity criteria. Adverse events after this period considered to
be possibly or probably related with study drug were also
recorded. Detailed blood analysis was performed weekly from
study week 3 –9 or until recovery and repeated at 13 and 26 weeks
and every 6 months thereafter until 2 years. Other toxicity
evaluations included blood chemistry and TSH assays for all
patients basically all 6 months up to 2 years. Long-term
evaluations after 2 years from treatment were performed every 6
months.
HAMA assay
The HAMA assay (HAMA Elisa, Medac, Hamburg, Germany) was
performed for all patients and had to be negative at inclusion. The
HAMA assay was repeated at 7, 13 and 26 weeks after therapy and
every 6 months thereafter.
Statistical analysis
Statistical analysis was performed for patients who had received
the therapeutic activity of radiolabelled antibody. PFS and OS were
analysed using the Kaplan Meier analysis of the UNISTAT 5.5s
statistical package for Windows (2002 edition, Unistat Ltd,
London, England, run on Windows XP). Survival differences
among patients subgroups were analysed using the Wilcoxon w2
statistics (Gehan evaluation). P-values o0.05 were considered
significant.
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RESULTS
In all, 18 patients were included in the study. Their characteristics
and their lymphoma history are shown in Table 1. Two patients
with transformed disease did not receive the administration of
therapeutic 131I-tositumomab activity because of rapid disease
progression during the dosimetry phase.
As concerning chemotherapy regimens, the eight patients
experiencing CR after RIT had a mean of 2.5 chemo/rituximab
treatments and one patient had RT before inclusion. In detail, 88%
of these patients had received anthracyclines, 75% alkylating
agents and 63% rituximab. The eight patients experiencing PR or
PD after RIT had a mean of 3.4 chemo/rituximab treatments and
two patients had RT before inclusion. In detail, all of these patients
had been treated with both anthracyclines and alkylating agents
and 75% with rituximab.
Pharmacokinetics
After the injection of the dosimetric activity of 185 MBq 131I-
tositumomab, the whole-body scintigraphies revealed a single
exponential radioactivity decrease in all patients with a mean
effective half-life of 64.278.7 h was observed (range 47.9– 77.8 h).
An average therapeutic activity of 2.970.6 GBq (range 1.9–
3.9 GBq) 131I-tositumomab was administered after a mean delay of
8 days after dosimetry (Figure 1). Immunoreactivity of two
arbitrarily selected therapeutic batches of 131I-tositumomab
revealed as very high at extrapolation to infinite antigen excess
with results ranging between 95.2 and 100%.
Response and survival
The overall response rate was 81% in the 16 patients treated,
including 50% CR/CRu and 31% PR. Median PFS of the 16 treated
patients was 22.5 months. Median overall survival has not been
reached after a median observation time of 48 months (Figure 2).
All 12 patients with indolent lymphoma responded, eight with
CR or CRu and four with PR. After a median follow-up of 45.5
months, the median PFS of the 12 indolent lymphoma patients has
not been reached. The PFS of the four patients in PR ranged from 6
to 17 months. Median PFS of complete responders (CR and CRu)
has not been reached but will be greater than 51 months (Figure 3).
In fact, only one of the eight CR/CRu patients presented a relapse
at 28 months. Another patient in CRu died from secondary
myelodysplastic syndrome (MDS) and leukaemia 45 months after
RIT, as described below. Six patients remain currently in ongoing
CR/CRu, two of them being disease free 4 years after therapy and
three others after more than 5 years. These six patients had
previously been treated with a mean of 2.7 chemo-immunotherapy
regimens (range 1– 5), two of them had also received radiotherapy.
Of the five patients treated with transformed disease, one had a
partial response that lasted 10 months. The three other patients
progressed and required further treatment before treatment-
related haematological toxicity was resolved.
w2 Wilcoxon analysis indicated a highly significant difference
(Po0.005) of PFS in patients with non-transformed (N¼ 12)
compared with transformed disease (N¼ 4). However, given the
very low number of patients with transformed disease who actually
received the RIT, this statistical comparison must be considered
Table 1 Patient characteristics (N¼ 18)
Age (years)
Median 52.3
Range 31–77
Sex
Male N¼ 8
Female N¼ 10
Lymphoma histology
Follicular N¼ 10
Small lymphocytic N¼ 1
Malt N¼ 1
Transformed N¼ 6
Stage at study entry
II N¼ 3
III N¼ 4
IV N¼ 11
Bulky tumour (largest diameterX5 cm) N¼ 14
Bone marrow involvement N¼ 7
Disease evolution from diagnosis to study entry (months)
Median 31.2
Mean 45.1
Range 8–121
Prior chemo-rituximab therapies
Mean 3.0
Range 1–6
Previous RT N¼ 4
Previous rituximab N¼ 10
Elevated LDH N¼ 7
Reduced platelet counts N¼ 4
Anterior Posterior
R RL
Figure 1 Anterior and posterior whole-body scans of patient Corixa Nr.
721 are shown recorded 6 days after injection of therapeutic 131I-
tositumomab activity (3.0 GBq). Antibody uptake is clearly visualized
(arrows) in the left jugular, right axillar, left mediastinal, right iliac and right
inguinal adenopathies. R¼ right, L¼ left. Thyroid uptake of 131I was
significant in this patient despite thyroid blockade with oral KI. Six days after
injection, blood pool activity remains high.
Long-term follow-up of 131I-tositumomab RIT
F Buchegger et al
1772
British Journal of Cancer (2006) 94(12), 1770 – 1776 & 2006 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
with caution. Other parameters were evaluated for patients with
non-transformed disease (N¼ 12). The analysis indicated that
stage of disease, bone marrow involvement, tumour size, age,
gender, number of previous chemotherapies, platelet counts, LDH
level, and time from initial diagnosis were not significantly linked
with treatment outcome (P40.25).
Toxicity
During first perfusion of unlabelled tositumomab, one patient had
a fall of blood pressure that required adjustment of the infusion
rate and another patient developed grade 2 abdominal pain
requiring opioid treatment.
All 16 treated patients showed either enhanced pre-existing or
newly developing bone marrow depression in at least two cell
lineages (Table 2). Bone marrow depression was minor (grade 1 or
2) in four patients. The other 12 patients showed grade 3 (five
patients) or 4 (seven patients) toxicity in one or more lineages. The
median degree of PMN, leukocyte and platelet depression after RIT
was grade 3, that of haemoglobin grade 1. The median duration of
toxicity greater than grade 2 was 21–27 (Table 2). One patient had
the leukocyte and PMN nadir particularly late and was recovering
from these grade 3 and 4 toxicities, respectively, after week 13.
Another patient with transformed disease required further
treatment 7 weeks after RIT because of disease progression while
still in grade 3 haematological toxicity. Some minor toxicities
grade 1 or 2 were still observed in the other 14 patients 13 weeks
post-treatment.
In all, 29 nonhaematologic side effects, mostly mild (grade 1 or
2) possibly or probably linked with RIT, were reported for nine
patients. They included pain, fatigue, fever, chills, sweating, rash,
arthralgia, erythaema and oedema, a pneumonia and a thyroiditis.
One febrile lymphadenitis during pancytopenia and one febrile
neutropenia, both grade 3, were observed at 7 and 8 weeks post
RIT and resolved both rapidly under antibiotic therapy. One
patient developed elevated TSH without requiring hormone
replacement.
Four patients developed HAMA. Interestingly, all positive
HAMA results were observed among the patients who responded
with CR/CRu, suggestive of a significant association (Po 0.05) in a
multigroup comparison according to Tukey-HSD. The four HAMA
positive patients are still alive without relapse.
The most serious adverse event was a myelodysplastic syndrome
(MDS) that appeared 34 months after RIT in one patient who
eventually died from secondary leukæmia. However, this patient
was previously treated with five cycles of chemotherapy (CHOP),
with which he reached a PR. At progression of disease, 19 months
later, he was treated with rituximab, but a major para-aortic mass
showed continued growth. He was included in the RIT study 40
months after initial diagnosis and initial CHOP chemotherapy
and he presented a bulky abdominal mass. RIT with 3.6 GBq
131I-tositumomab resulted in CRu without further change over the
rest of follow-up (stable CT over more than 2 years). MDS was
diagnosed 34 months after RIT and 74 months after initial
chemotherapy. It evolved into secondary leukaemia with fatal
outcome 11 months later.
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Figure 2 Kaplan–Meier plots show OS and PFS of the 16 treated
patients, 12 presenting with indolent relapsed lymphoma and four with
transformed disease.
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Figure 3 Kaplan–Meier plots show PFS of 13 responding patients, 12
presenting with relapsed indolent lymphoma and one with transformed
disease. Results are shown according to the response, PR or CR/CRu. Note
that of the eight patients with CR/CRu, one patient has relapsed at 28
months and one patient died at 45 months from secondary leukaemia, the
other six patients are in ongoing CR/CRu.
Table 2 Haematological toxicity in 16 treated patients
WBC Neutrophils Platelets Hæmoglobin
Median nadir value (Counts mm3 or g/l, respectively) 1900 600 29 000 109
Median time to nadir (days) 47.5 49 41 58
Range 35–81 35–81 35–62 41–76
Median duration of toxicity grade 3 or higher (days) 20.5 27 26
Range 8–56 7–49 6–61 (21 & 26)a
Toxicity (%)
Grade 3 or 4 69 69 56 13
Grade 4 19 38 6 Ø
aOnly two patients had haemoglobin toxicity grade 3. Duration was 21 and 26 days, respectively.
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DISCUSSION
Results of 16 patients treated with 131I-tositumomab RIT for
relapsed indolent or transformed lymphoma are presented. The
long-term results in low-grade disease are very encouraging,
considering that 6 out of 12 patients are disease free after 46 to 70
months.
The initial phase I-II studies with 131I-tositumomab reported CR
in approximately one third of the patients, with half of them
relapsing within 20 months (Kaminski et al, 2000). The CR rate
was 20% in the pivotal study, and half of these complete
responders remained disease free for more than 4 years (Kaminski
et al, 2001). A more recent report (Davies et al, 2004) showed 20
CR/CRu (49%) out of 41 patients treated, with a median duration
of the CR/CRu not yet reached, but will exceed 2.5 years. Our
results compare well with these previous studies, showing 50% CR/
CRu, the median PFS for these patients being not reached after a
median follow-up of 44 years. Such an outcome is unusual in this
population of largely pretreated patients, considering that the
natural history of indolent lymphomas is typically characterized by
continuous relapses with remissions becoming shorter after each
progression (Gallagher et al, 1986). It is impressive to note that two
of the patients who were in relapse after 4 or 5 lines of chemo-
immunotherapy remain in CR 61 and 67 months following RIT.
The impressive efficacy of 131I-tositumomab in some patients
with chemotherapy resistant disease, would suggest that RIT
should be used earlier in the treatment course of indolent
lymphoma for optimal clinical benefit. To explore this hypothesis,
a recent analysis of more than 1000 patients was conducted to
examine the efficacy of 131I-tositumomab by line of therapy. This
analysis revealed that both the frequency of long-term durable
responders and the rate of CR was higher when 131I-tositumomab
was used earlier in the treatment sequence (Gregory et al, 2005).
Interesting results have also been reported for follicular lymphoma
treated upfront with a single treatment of 131I-tositumomab
(Kaminski et al, 2005). In this latter study, CR were observed in
75% of patients, relapse free survival of these patients was 77%
at 5 years. Impressive results have also been observed when
131I-tositumomab has been combined with chemotherapy in the
upfront setting (Press et al, 2003; Leonard et al, 2005). Rituximab
has been shown to improve the outcome of patients with
previously untreated follicular lymphoma when associated with
chemotherapy (Marcus et al, 2005). Several other reports suggest
that first line combination of rituximab and anthracycline-
containing chemotherapy is able to induce very high response
rates and prolonged remission, including molecular remission
(Hiddemann et al, 2003; Salles et al, 2004; Zinzani et al, 2004;
Czuczman et al, 2005). Both chemo-immunotherapy and RIT
appear as attractive options for treatment of indolent lymphoma,
but the best long-term strategy still needs to be determined. A
randomized phase III study by the SWOG comparing R-CHOP to
131I-tositumomab-CHOP is currently ongoing and will address the
question of the optimal treatment in the front-line setting.
The results published by Davies et al (2004) and our data
suggest that 131I-tositumomab RIT is at least equivalent to 90Y-
ibritumomab tiuxetan (Zevalins) (Gordon et al, 2004b). Indeed, in
the rituximab refractory setting, efficacy may be more favourable
for 131I-tositumomab when reviewing two separate phase II studies
of both these agents. The PFS for responders treated with 131I-
tositumomab was 24.5 months vs 8.7 months for similar patients
treated with 90Y-ibritumomab tiuxetan (Witzig et al, 2002a;
Horning et al, 2005). This observation may be explained by the
fact that the unlabelled antibody used with ibritumomab tiuxetan
is rituximab, which was being administered to patients who
were already resistant to rituximab. The efficacy results of
131I-tositumomab also compared favourably with 90Y-ibritumomab
tiuxetan in two separate recent analyses of the long-term durable
responder patient populations (defined as time to progression of
X12 months) treated with both these agents (Fisher et al, 2005;
Wiseman and Witzig, 2005). Compared with rituximab in a
randomized phase III study, 90Y-ibritumomab tiuxetan was shown
to induce 34% of CR/CRu vs 20% for rituximab and a median time
to progression (TTP) of 15 versus 10.2 months. In patients who
achieved CR/CRu TTP was 24.7 months for RIT and 13.2 months
for rituximab alone (Gordon et al, 2004b). Other phase II trials
with 90Y-ibritumomab tiuxetan reported CR/Cru rates between 15
and 51% (Wiseman et al, 2002; Witzig et al, 2002a; Gordon et al,
2004a) the follow-up being frequently shorter compared with the
present study or that of Davies (Davies et al, 2004). Therefore, it is
clear that both agents have demonstrated high levels of efficacy in
patients with relapsed/refractory disease.
In the present study, we observed a single patient who developed
secondary myelodysplasia 34 months after RIT and 74 months
after first-line chemotherapy. The standard CHOP chemotherapy
or/and 131I-tositumomab RIT may have contributed to this
evolution. Both the alkylating agents and doxorubicin, constituents
of CHOP, are known to induce increased risk of myelodysplasia
and secondary leukaemia, as does also total body irradiation
(Armitage et al, 2003). The risk of MDS seems to be particularly
increased when radiotherapy (RT) is associated with alkylating
agents. It is globally estimated that 10% of patients treated for
lymphoma will develop secondary MDS/AML within 10 years of
primary therapy (Armitage et al, 2003). Thus, the myelodysplasia
developing 74 months after initial therapy in a single patient does
not allow to conclude on the role of RIT in the course of the illness
of this patient. It is also noted that no secondary myelodysplasia
was observed in the other report from the English group using the
same treatment protocol (Davies et al, 2004), and that large cohort
studies analysing patients treated with RIT did not show any
obvious increase in the incidence of secondary MDS/AML,
compared with similar patients treated with conventional therapies
(Witzig et al, 2003; Bennett et al, 2005). In addition, when 131I-
tositumomab was administered as a single agent in the front-line
setting, no cases of MDS/AML were observed after 5 years of
follow-up (Kaminski et al, 2005).
Both 131I-tositumomab and 90Y-ibritumomab tiuxetan RIT
consist of a combination of radiolabelled with unlabelled antibody.
The unlabelled antibody, however, might not be used optimally. A
randomized study performed in patients with follicular lymphoma
has shown that different schedules using rituximab in maintenance
following the standard 4 weeks treatment were significantly
improving the event free survival of responders (Ghielmini et al,
2004). As RIT is given in a similar patient population, higher
overall and complete response rates and longer event-free survival
might possibly be achieved by using prolonged treatment with
unlabelled antibody following RIT administration.
Another remark concerns the half-life of 131I-tositumomab. It
has been argued that a long-lived radiolabelled antibody might
induce bone marrow and normal tissue toxicity, whereby limiting
the amount of activity that can be administered, but there have
never been any published clinical data reported to support this
theory, to our knowledge. In the 16 patients treated here, 131I-
tositumomab showed a mean whole-body half-live of 64.2 h. In
comparison, 90Y-Zevalin was reported to have a median blood
effective half-live of 27 h (Wiseman et al, 2003). The observed
efficacy of 131I-tositumomab rather argues against the hypothesis
that antibodies labelled with longer-lived radionuclides are
potentially more harmful than those with shorter-lived radio-
nuclides. Instead, one might argue that the observed efficacy of
131I-tositumomab could be linked with the prolongation of
therapeutic radiation delivery over several days, allowing therefore
repair, repopulation, redistribution and reoxygenation processes
to occur in tumour and normal tissues, as it is the case in standard
fractionation radiotherapy (Thames and Hendry, 1987).
A final comment concerns the observation of HAMA in the
group of CR patients with long-term survival. Indeed, appearance
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of HAMA could potentially also induce anti-HAMA antibodies,
which could in turn be anti-idiotype antibodies and therefore
directed against CD20. Since anti-CD20 antibodies are efficient as
lymphoma therapy, anti-idiotype antibodies developed by the
patient could represent a long-term treatment to lymphoma
provided by the patient himself. However, since tositumomab is a
mouse antibody, the HAMA response most probably represents an
anti-constant domain antibody and not an anti-idiotype. The
correlation of positive HAMA in connection with long-term
tumour-free survival might, therefore, rather reflect a preserved
immune competence of these patients. Preserved immune compe-
tence could be decisive in connection with the use of the unlabelled
antibodies that develop efficacy based probably on ADCC and CDC
as shown by different studies. Interestingly, a recent report,
published while this article was reviewed (Azinovic et al, 2006),
also described a survival benefit associated with HAMA.
CONCLUSION
Our data have shown high overall and complete response rates
combined with the observation of long-term progression free
survivals of CR/CRu in recurrent indolent NHL. Toxicity was mild
except in one patient who developed a secondary myelodysplastic
syndrome that evolved into secondary leukaemia. However, this
observation does not allow any particular deduction at this time
on the part of RIT in the cause of this disease. Overall, these
data confirm and extend the previously reported results with
131I-tositumomab, a treatment shown to be able to bring a
significant number of indolent, relapsed NHL into long-lasting
complete responses. Our findings in patients at first or second
relapse, along with other published reports, also suggest that 131I-
tositumomab should be administered early in the course of
relapsed disease for optimal clinical benefit.
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